DANAHER CORP /DE/ (DHR) Form 8-K — Oct 20, 2026
Danaher reported better-than-expected Q3 2026 results, with revenue up 8.5% year-over-year to $6.6 billion and adjusted diluted EPS up 11.5% to $2.11. Core revenue grew 3.0% (5.5% excluding respiratory testing), and free cash flow rose roughly 19% year-over-year to $1.6 billion. CEO Julie Sawyer Montgomery highlighted improving end-market trends and DBS-driven execution. The company raised its full-year 2026 adjusted diluted EPS guidance to $8.57-$8.62 from $8.45-$8.60, and guided Q4 core revenue ex-respiratory growth of 4.0%-5.0%.
Key figures
- Eps
- 1.71
- Revenue
- 6554000000
- Guidance
- Q4 2026 core revenue ex-respiratory growth of 4.0%-5.0%; full-year 2026 adjusted diluted EPS raised to $8.57-$8.62 from $8.45-$8.60; Q4 adjusted operating margin ~29.5%
- Net Income
- 1207000000
- Cash Position
- Free cash flow of $1.6 billion in Q3; operating cash flow of $1.9 billion
- Adjusted eps q3
- 2.11
- Free cash flow q3
- 1632000000
- Operating cash flow q3
- 1886000000
- Q3 discrete tax benefit
- 263000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.